Hypothesis

Circadian disruption drives a distinct senescent phenotype in endometrial stromal cells through loss of BMAL1‑mediated repression of NF‑κB signaling. BMAL1 normally partners with SIRT1 to deacetylate the RelA/p65 subunit of NF‑κB, suppressing a senescence‑associated secretory phenotype (SASP) that includes IL‑6, TGF‑β, and PAI‑1. When BMAL1 declines, hyperacetylated p65 activates a transcriptional program that creates a CDKN1A^hi/CDKN2A^hiIL6^TGFB1^+ senescent stromal subpopulation. This subpopulation secretes factors that impair decidualization of neighboring stromal cells, establishing a causal link between clock dysfunction, stromal senescence, and implantation failure.

Mechanistic Reasoning

1. BMAL1‑SIRT1 complex – In young endometrial stromal cells, BMAL1 recruits SIRT1 to the promoter of NF‑κB target genes, leading to deacetylation of RelA/p65 and reduced transcriptional activity.
2. Loss of BMAL1 – Decreased BMAL1 (as seen in recurrent miscarriage and implantation failure) disrupts this complex, causing RelA/p65 hyperacetylation, increased NF‑κB drive, and upregulation of SASP cytokines.
3. Senescent stromal subprogram – The SASP reinforces a stable growth‑arrest state (via CDKN1A/CDKN2A) and creates a paracrine milieu that blocks progesterone‑induced decidual markers (PRL, IGFBP1).
4. Feedback loop – SASP factors further suppress BMAL1 expression through inflammatory signaling, amplifying the senescence clock.

Testable Predictions

• Prediction 1: Single‑cell RNA‑seq of endometrial stromal cells from aged or BMAL1‑deficient mice will reveal a unique cluster co‑expressing Cdkn1a, Cdkn2a, Il6, Tgfb1, and Serpine1, absent in young controls.
• Prediction 2: Genetic deletion of Bmal1 specifically in endometrial stromal cells (using Amhr2‑Cre; Bmal1^fl/fl) will expand this senescent cluster and reduce decidualization rates after in vivo progesterone challenge.
• Prediction 3: Pharmacological activation of SIRT1 (e.g., with resveratrol or SRT2104) or circadian enhancement (e.g., Nobiletin) will decrease RelA/p65 acetylation, shrink the senescent cluster, and rescue decidualization markers in Bmal1‑deficient stromal cells.
• Prediction 4: Blocking NF‑κB signaling (with IKKβ inhibitor BMS‑345541) in Bmal1‑null stromal cells will prevent SASP induction despite low BMAL1 levels.

Falsifiability

If scRNA‑seq of Bmal1‑deficient endometrial stromal cells fails to show an increase in a Cdkn1a^hiCdkn2a^hiIl6^Tgfb1^+ senescent subpopulation, or if SIRT1 activation does not reduce this cluster or improve decidualization, the hypothesis that BMAL1‑SIRT1‑NF‑κB axis gates a senescence program driving implantation failure would be falsified.

Experimental Approach

1. Mouse model: Generate Amhr2‑Cre; Bmal1^fl/fl females; validate stromal‑specific Bmal1 loss by qPCR and immunohistochemistry.
2. scRNA‑seq: Isolate endometrial stromal cells at estrus stage; perform 10x Genomics sequencing; identify senescent cluster via canonical markers and SASP genes.
3. Intervention groups: (a) Vehicle, (b) SIRT1 activator, (c) Nobiletin, (d) IKKβ inhibitor; treat ex vivo stromal cultures or administer in vivo for 7 days.
4. Readouts: (i) Percentage of senescent stromal cluster, (ii) RelA/p65 acetylation (Western blot), (iii) Decidualization assay (PRL/Igfbp1 expression after progesterone + cAMP), (iv) Implantation sites counted after embryo transfer.

Implications

Confirming this mechanism would position circadian enhancers and SIRT1 agonists as geroprotective agents specifically targeting stromal senescence in the endometrium, offering a precision strategy to counteract age‑related reproductive decline without broadly suppressing senescence elsewhere.